Kite, a Gilead Company, “announced data from follow-up analyses of three studies of Yescarta, or axicabtagene ciloleucel, that demonstrate the long-term survival potential for patients living with several sub-types of relapsed or refractory non-Hodgkin lymphoma, which were presented at the 65th American Society of Hematology Annual Meeting & Exposition. This included ZUMA-1 showing that patients with refractory large B-cell lymphoma who maintained a complete response at 12- and 24-months following treatment with Yescarta had a 72-month estimated disease-specific survival of 94.4% and 100%, respectively.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GILD:
- Ideaya Biosciences enters clinical study pact, supply agreement with Gilead
- Gilead management to meet with Oppenheimer
- Cabaletta Bio, Gracell slide as FDA probes risk of CAR T cell immunotherapies
- FDA probing risk of T-cell malignancy following CAR T cell immunotherapies
- Aurinia strength may be related to Gilead suspicion, says Gordon Haskett
